imatinib mesylate has been researched along with Anemia, Cooley's in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, R; Gurkan, UA; Kalfa, T; Little, JA; Low, PS; Man, Y; Noomuna, P; Risinger, M; Seu, K; Sheik, DA; Turrini, FM; Wan, J; Zhou, S | 1 |
| Pericay Pijaume, C; Saigi Grau, E | 1 |
2 other study(ies) available for imatinib mesylate and Anemia, Cooley's
| Article | Year |
|---|---|
Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Anion Exchange Protein 1, Erythrocyte; beta-Thalassemia; Cell Adhesion; Cell-Derived Microparticles; Drug Evaluation, Preclinical; Endothelium, Vascular; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes, Abnormal; Hemoglobin, Sickle; Humans; Imatinib Mesylate; Oxidative Stress; Oxygen; Phosphorylation; Phosphotyrosine; Plasma; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sickle Cell Trait | 2020 |
Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor.
Topics: Aged; Antineoplastic Agents; Benzamides; beta-Thalassemia; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome; Vitamin B 12; Vitamin B 12 Deficiency | 2012 |